Abstract. Studies on thyrotropin receptor autoantibodies (TRAb) by measurement of both thyroid-stimulating antibodies (TSAb) and thyrotropin-binding inhibitory immunoglobulins (TBII) in serum from children with Graves' disease are limited in number of studies. The aim of this study was to investigate the levels of serum TSAb and TBII in children with Graves' disease, and to evaluate the clinical significance of these antibodies. We measured the serum TSAb and TBII at diagnosis and during management in 65 children with Graves' disease. Patients were divided into four groups according to their metabolic state: those with untreated active Graves' disease, those receiving treatment with antithyroid drugs, those in remission, and those in relapse. At diagnosis, both TSAb and TBII assays had high sensitivities and high specificities. In follow-up, the levels of both TSAb and TBII paralleled the course of the disease. There was a strong positive correlation between TSAb and TBII. TBII levels were significantly higher in the patients with ophthalmopathy than those without ophthalmopathy in untreated Graves' children. It was concluded that TSAb and TBII measurements are valuable in the diagnosis and management of children with Graves' disease.
THE pathogenetic role of thyrotropin receptor autoantibodies (TRAb) in the serum of patients with Graves' disease has been widely accepted [1, 2] . Today, two kinds of assays are used to detect TRAb [3, 4] . One is based on the competition between the antibody and thyrotropin (TSH) for binding to the TSH receptor [thyrotropin-binding inhibitory immunoglobulins (TBII)]. The other is a functional assay that measures the production of cAMP in response to a TSH receptor interaction with stimulating antibodies [thyroid-stimulating antibodies (TSAb)] or blocking antibodies [thyroid stimulation blocking antibodies (TSBAb)]. The competitive assay does not distinguish between the TRAb that stimulates or blocks the TSH receptor. Only functional assays can identify whether the antibody is a stimulating antibody or a blocking antibody.
TRAb has a heterogeneous nature and multiple forms of TRAb are found [3, [5] [6] [7] . TSAb and TBII reflect different aspects of TRAb, hence the simultaneous measurement of both TSAb and TBII is clinically useful [3, 8, 9] .
However, studies on TRAb by measurement of both TSAb and TBII in serum from children with Graves' disease are limited in number [10] [11] [12] [13] , and the use of TRAb testing in routine clinical practice in diagnosis and follow-up of Graves' disease is debated [14, 15] . The aim of the present study was to investigate the prevalence of serum TSAb and TBII in children with Graves' disease, and to evaluate the clinical significance of these antibodies. Furthermore, to investigate the influence of age on disease characteristics, we com-pared our experience with the clinical and biochemical findings in younger (age <13 yr) and older (age ³13 yr) children with untreated Graves' disease.
Subjects and Methods

Patients
Sixty-five serum samples obtained from children with Graves' disease were studied. Their median age at diagnosis was 12.4 years (range 5.1 to 17.5 years). A diagnosis of Graves' disease was made on the basis of clinical and biochemical evidence of hyperthyroidism (suppressed TSH, elevated 3,5,3'-triiodothyronine (T 3 ), thyroxine (T 4 ), free T 3 or free T 4 , goiter, increased thyroidal uptake of 123 I, and signs of Graves' ophthalmopathy when present). Patients who had eyelid retraction, eyelid lag, or proptosis were defined as subjects with ophthalmopathy. Patients were divided into four groups according to their metabolic state: those with untreated active Graves' disease (group I, n = 35), those receiving treatment with antithyroid drugs for longer than 4 weeks (group II, n = 19), those in remission (group III, n = 6), and those in relapse (group IV, n = 5). Sera for control measurements were obtained from 34 euthyroid individuals undergoing treatment of non-thyroidal illness (growth hormone deficiency, type 2 diabetes mellitus) at the Pediatric Endocrine Clinic of Kitasato University Hospital (group V, n = 34). The clinical data of the patients are summarized in Table 1 .
Serum thyroid hormones and TSH were measured at the time the patients were seen. Before December 2001, T 3 , T 4 and TSH were measured by immunoradiometric assay kits with T-3 Riabead, T-4 Riabead and TSH Riabead (Abbott Japan, Chiba, Japan), respectively, and free T 3 and free T 4 were measured with Amerlite-MAB FT 3 and Amerlite-MAB FT 4 (Ortho-Clinical Diagnostics, Buckinghamshire, UK), respectively. After December 2001, T 3 , T 4 , free T 3 , free T 4 and TSH were measured by electrochemiluminescence immunoassay system with Elecsys T 3 , Elecsys T 4 , Elecsys free T 3 , Elecsys free T 4 and Elecsys TSH, respectively (Roche Diagnostics GmbH, Mannheim, Germany). The reference ranges used for serum T 3 , T 4 , free T 3 , free T 4 and TSH were 70 to 180 ng/dl, 5.2 to 12.4 mg/dl, 2.5 to 4.3 pg/ml, 1.0 to 1.8 ng/dl, and 0.30 to 4.00 mU/L before December 2001, and after then, 80 to 160 ng/dl, 6.10 to 12.4 mg/dl, 2.30 to 4.30 pg/ml, 0.90 to 1.70 ng/dl, and 0.500 to 5.00 mU/L, respectively.
Furthermore, group I was divided into younger (age <13 yr, n = 15) and older (age ³13 yr, n = 20) patients.
Autoantibody measurements
Sera for TSAb and TBII measurements were collected and stored at -30°C until assay.
TSAb Assays. TSAb was measured as a percent increase in cAMP production by porcine thyroid cells with TSAb assay kit Yamasa (Yamasa Co., Choshi, Chiba, Japan) [16, 17] . Sera whose TSAb levels were Values given are medians, with the range in parentheses.
higher than 1000% were diluted and measured again. The intra-and interassay coefficients of variation of TSAb were 3.3% and 19.4%, respectively. TBII assays. TBII was measured by a radioreceptor assay kit using porcine thyroid membrane with quantitative TRAb 125 I RRA kit (DiaSorin Inc., Stillwater, MN, USA) following the manufacturer's instructions, and the results were expressed in units (U) based on the WHO standard (LATS, MRC Research Standard B, Code 65/122) [18] . Briefly, 50 ml of standard solution or serum and 50 ml of solubilized porcine thyroid membrane were mixed and incubated for 15 min at room temperature, and then 100 ml of 125 I-labeled bovine TSH was added and incubated for 2 h at room temperature. Then, 1 ml of chilled precipitation solution was added. Tubes were centrifuged at 2200 g at 4°C for 30 min, and radioactivity in the pellets was measured. Sera whose TBII levels were higher than 100 U/L were diluted and measured again. The intraand interassay coefficients of variation of TBII were 8.8% and 8.6%, respectively.
Statistical analyses
To define the clinical cut-off level for positive serum with TSH receptor antibodies, we performed receiveroperating characteristic (ROC) plot analysis of the data from the patients in group I (untreated Graves' disease) and group V (controls) [19, 20] . The sensitivity and specificity were plotted on an ROC curve. The sensitivity (true positive ratio) was calculated from the 35 untreated Graves' patients in group I. The specificity (true negative ratio) was calculated from 34 controls in group V. Statistical analysis was performed using Mann-Whitney rank sum analysis for comparison of the autoantibody levels in the different groups determined with one assay. Correlation analysis was performed with Pearson's correlation. Fig. 1 shows plots of the sensitivity and specificity of the TSAb assay and those of the TBII assay. From ROC curves, 180% was chosen as the cut-off value for TSAb and 8 U/L for TBII. Of the 35 untreated Graves' patients, 33 (94.3%) had positive TSAb, and 32 (91.4%) had positive TBII.
Results
The distributions of the autoantibody levels of the TSAb assay and that of the TBII assay in groups I-V are shown in Figs. 2A and 2B, respectively. There were significantly higher autoantibody levels in groups I, II and IV than in the control group in both assays (by Mann-Whitney rank sum analysis: groups I and II, p<0.01; group IV, p<0.05). There were significantly lower autoantibody levels in group II than in group I in both assays (p<0.01). All of the subjects in group III had both negative TSAb and TBII, and all but one in group IV had both positive TSAb and TBII. Two patients in group I displayed neither TSAb nor TBII. They had mild hyperthyroidism. They did not exhibit ophthalmopathy.
There was a strong positive correlation between the data obtained in the TSAb assay and those obtained in the TBII assay in group I as shown in Fig. 3 (r = 0.80, p<0.001). There were also strong positive correlations between the data obtained in these two assays in groups II, IV, and all Graves' children (r = 0.74; n = 19; p<0.001, r = 0.92; n = 5; p<0.05 and r = 0.80; n = 65; p<0.001, respectively; data not shown).
In addition, in Fig. 3 , the closed dots indicate the data of patients with ophthalmopathy, and the open dots indicate those of patients without ophthalmopathy in group I. TSAb levels were not significantly higher in the patients with ophthalmopathy (median, 525.9%; range, 201.1%-4568.7%) than those without ophthalmopathy (median, 428.3%; range, 137.2%-918.5%). There were no significant differences of the levels of thyroid hormones between those with ophthalmopathy and those without ophthalmopathy in group I (data not shown). The serum thyroid hormones, serum TSH, the incidence of ophthalmopathy, and the titers of both TSAb and TBII were not statistically different between younger (age <13 yr) and older (age ³13 yr) patients in group I.
Discussion
From the ROC curves, it was indicated that both TSAb and TBII assays had high sensitivity and high specificity at diagnosis. In follow-up, the levels of both TSAb and TBII in groups I-IV paralleled the course of the disease, hence, TSAb and TBII measurements are valuable in the diagnosis and follow-up of children with Graves' disease. Both TSAb and TBII assays are commercially available and do not require culture facilities, and so their use is not limited to specialized laboratories. Although the use of TSAb and TBII testing in routine clinical practice in diagnosis and follow-up of Graves' disease remains controversial [14, 15] , these methods may be the most sensitive and specific procedures for the diagnosis and management of Graves' disease. Two patients with negative TSAb and negative TBII in group I had mild disease, which is similar to that reported by others [21, 22] .
We observed a strong positive correlation between TSAb and TBII in groups I, II, IV, and all Graves' children. It is reported that children with atrophic autoimmune thyroiditis (AAT) did not possess TSBAb, which are often found in adult patients with AAT [23] . Similarly, it is possible that children with Graves' disease seldom possess TSBAb, and so the correlations between TSAb and TBII might be strongly positive. Another possible reason for our strong correlation is the characteristics of our methods. The TSAb assay and TBII assay which we used were semi-quantitative assay and quantitative assay, respectively, so they can detect high levels without bluntness.
The finding of 42.9% incidence of ophthalmopathy in group I is similar to that found in other reports of juvenile Graves' disease [24] [25] [26] . In group I, the children with ophthalmopathy had significantly higher TBII titers than those without ophthalmopathy, which is similar to that of children with Graves' disease reported by others [27] . In group I, TSAb levels were not significantly higher in the Graves' children with ophthalmopathy than those without ophthalmopathy. However, it is reported that TSAb was correlated with the severity of ophthalmopathy in adult Graves' disease [28, 29] . The clinical and biological findings of Graves' disease, including ophthalmopathy, are different with age [4, 24, 25, 27, [30] [31] [32] [33] , and so it is possible that this difference might be due to age. However, we examined only the presence of ophthalmopathy, and not its severity, hence further evaluation is needed.
In the present study, no difference was seen between younger and older patients in group I. This is probably due to the small number of patients in each group.
In conclusion, both TSAb and TBII measurements are valuable in the diagnosis and follow-up of children with Graves' disease.
